Alterna Wealth Management Inc. Buys Shares of 10,000 Atyr PHARMA INC (NASDAQ:ATYR)

Alterna Wealth Management Inc. purchased a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,000 shares of the company’s stock, valued at approximately $36,000.

Separately, Kingswood Wealth Advisors LLC purchased a new position in Atyr PHARMA during the 4th quarter valued at about $170,000. Institutional investors own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They set an “overweight” rating for the company. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Atyr PHARMA currently has a consensus rating of “Buy” and a consensus price target of $19.25.

Atyr PHARMA Stock Up 3.2 %

NASDAQ:ATYR opened at $3.86 on Monday. Atyr PHARMA INC has a 12-month low of $1.42 and a 12-month high of $4.22. The company’s 50-day moving average is $3.48 and its two-hundred day moving average is $2.69. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). Research analysts expect that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.